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ABSTRACT
Despite the significant improvement of knowledge and technologies in tumor treatments, pancreatic
tumor remains a complex disease still characterized by a poor prognosis. The increasing role of minim-
ally invasive techniques started to drive the effort of scientific medicine to evaluate the possibilities of
application of these techniques to pancreatic cancer. The purpose of this paper is to present a brief
summary of the different ablative techniques available and proposed for pancreatic tumor treatment
considering invasive, noninvasive, thermal and non-thermal techniques.
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Introduction
Pancreatic tumor remains a challenging issue in the medical
field. Despite the improvements that are occurring in last
years in all clinical fields, pancreatic cancer is still burdened
by poor prognosis and the gold standard for treatment
when possible is surgery [1]. Unfortunately, less than 20% of
patients is eligible for pancreatectomy at the diagnosis; the
remaining patients are treated with systemic therapy that
leads anyway to a 5-years survival less than 5% [2]. These
assumptions drove research efforts to find other approaches
to support systemic therapy such as radiotherapy [3] or other
minimally invasive procedures [4].
Image guided ablations are gaining increasing attention
in the current clinical practice providing reduced invasive-
ness, good outcomes and low morbidity in the treatment of
several different tumors (e.g., liver, kidney, lung) [5–10].
Particularly, improvements in imaging-guidance methods
and ablative technologies are contributing to the large diffu-
sion of ablative techniques, and for expanding their possible
applications in more and more difficult and complex scen-
arios [11–14]. Dealing with pancreatic cancer, the main indi-
cation for locoregional treatments is pain palliation in
advanced stages.
The purpose of this paper is to present the different abla-
tive techniques available and proposed for pancreatic tumor
treatment that can be divided into:
 invasive – thermal techniques;
 invasive – non-thermal techniques;
 noninvasive thermal techniques.
Invasive – thermal techniques
These techniques are mostly represented by radiofrequency
ablation and microwave ablation (RFA and MWA), but other
techniques as laser ablation and cryoablation were devel-
oped in last years. They are considered minimally invasive
techniques because of the requirement of needle positioning
in the tumor, that can be performed percutaneously or dur-
ing laparoscopic o laparotomic surgery.
RFA
Radiofrequency ablation induces coagulative necrosis within
the tumor mass through the production of high tempera-
tures, induced by the application of high-frequency alternat-
ing current. RFA represents the oldest thermal technique
available and several papers were published on its applica-
tion on different tumors and organs [15–17]. The current
technology allows ablation areas up to 5 cm of diameter
requiring long ablation time, the application of a large area
contact plate on the patient’s skin (which could cause
skin burns).
The temperature reached during the ablation seems to
correlate with complication, for this reason some authors
proposed to avoid more than 90 C temperatures [18–20].
While endoscopic ultrasound (EUS) is safer for lesions in the
pancreatic head, the percutaneous approach can be adopted
for lesions located in the body of the pancreas [20].
Few papers deal with percutaneous approach, ultrasound
(US) or computed tomography (CT) guided [21,22], while the
larger amount of data available are on laparotomic surgery
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[23] and no direct comparative study were performed. About
20% of patient presents a post-operative complication
related to the RFA, the more frequent ones being pancreatic
fistula, portal thrombosis and pancreatitis [4]. Even data on
mortality are widely different, Wu et al. report a mortality
rate of 25% mostly due to massive post-operative hemor-
rhage [24].
Data on follow-up are not constantly reported and have a
wide range; OS ranges from 0% to 100% with observation
lasting from 10 to 34 months [21–23].
Survival benefits are suggested from a comparative study
between patients receiving chemotherapy alone vs. chemo-
therapy plus RFA with mean overall survival rising to
20 months for combined approach from 13 months of the
chemotherapy alone group [25].
MWA
MWA is a relative newer technique compared to RFA and
data on clinical application on pancreatic tumors are even
less [26,27]. The MW unit consists of a microwave generator
and a cooled shaft antenna. Erogated energy could be
pulsed or continuous at 2450MHz, at this frequency waves
are mainly absorbed by water, causing heating over 100 C.
Data available on pancreas tumors are presented by case
reports or series reporting the experience with up to 20
cases [28–30].
The main objective of these studies was to evaluate the
feasibility and safety of percutaneous MWA. Complication
rates reported are extremely low, with one major complica-
tion reported (one month delayed pseudoaneurysm of the
gastroduodenal artery) and only few minor ones, such as
pain, delayed pancreatitis (one month after the procedure)
and pseudocyst. Even data on follow-up are poor but overall
survival rate reported at 1 year reaches 80%. It has already
been demonstrated that MWA offers several technical advan-
tages over RFA in liver ablation, such as higher ablation vol-
umes, shortened treatment duration and lower susceptibility
to the heat-sink effect and we can suppose that these advan-
tages will be reported even on pancreatic MWA.
Laser
Laser is coherent light beam that heats tissues interacting
with them. Light penetrates the tissue and is absorbed and
scattered in the tissue converting the energy in heat. The
heating of the tissue by means of light depends on the
absorption capability of the tissue itself [31]. Due to the very
small caliber of the applicators, laser has been used in the
ablation of tumors in critical locations [32–36].
Laser ablation technique provides the insertion of one or
more needles in the lesion in order to insert an optical fiber
which will deliver laser light. Needle positioning could be
performed percutaneously or during endoscopy (EUS
guided), anyhow few cases or series reporting endoscopic
procedures are available in the literature [4,37,38].
The largest series presents the data of nine patients with
lesion size ranging from 21mm to 45mm. The patients were
divided into three groups and treated with a total delivered
energy of 800, 1000 and 1200 J, at a low-power setting (2, 3
and 4 W), respectively. All the procedures were performed
under EUS guidance to avoid adjacent structures as vessels
and to detect intraprocedural complication (none was
reported). EUS was also used for real-time procedure moni-
toring. Additionally, in all cases, a contrast enhanced ultra-
sonography was performed before and after LA. In all cases,
the EUS revealed a hyperechoic area. Regarding the clinical
short-term outcomes, no major events were recorded. Three
patients reported a post-procedural fluid collection, while a
threefold increase in the amylase serum level was evidenced
in other two patients. All of them were successfully treated
conservatively. Follow up was performed at 24 h, 7 and
30 days after the ablation by means of CT scans. In all the
follow-up periods, a clear margin ablation was evidenced
with a gradual involution of the ablated areas. One patient
died due to a not procedure related myocardial infarction
before the 30-day CT scan reevaluation (mortality rate of
11%). Median OS was 7.4 months (range 29–662 days).
Cryoablation
Cryoablation freezes tissues to temperatures lower than
20 C and determine cell membranes destruction due to
intracellular and extracellular ice formation. Also, indirect cel-
lular damage results from disruption of the vascular endothe-
lium. This technique has been successfully applied in the
treatment of several different kind of tumors [8,10,14,39]. To
date, cryoablation has not been widely used in the treatment
of pancreatic tumors primarily due to the small volume of
the pancreatic gland, fragile pancreatic parenchyma and its
proximity to structures such as the stomach, duodenum,
colon, common bile duct and vessels. Few reports are avail-
able dealing with pancreatic cryoablation feasibility [40,41].
Complication rates were significant with about 10% of major
complication and up to more than 50% of minor complica-
tion. A study involving 49 patients with locally advanced
pancreatic cancer who received intraoperative cryosurgery or
percutaneous cryosurgery in a single institution hospital
between March 2001 and November 2007 showed that
median survival was 16.2 months and overall survival rates at
6, 12, 24 and 36 months were 94.9%, 63.1%, 22.8% and
9.5%, respectively [41].
An interesting application of cryoablation could be the
combination with immune therapy; cryotherapy not only
promotes tumor cell necrosis but also enhances the antitu-
mor immune response. In 2013, Niu et al. [42] retrospectively
assessed the effect of immunotherapy combined to cryo vs.
chemotherapy showing that the median overall survival
times in the cryoimmunotherapy and cryotherapy groups (13
and 7 months, respectively) were significant longer than
those in the chemotherapy group (3.5 months).
Invasive non-thermal techniques
Irreversible electroporation
Irreversible electroporation (IRE) is the newest and most
promising invasive technique for pancreatic cancer ablation.
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IRE is based on the application of short high-voltage electric
pulses, in order to produce multiple micropores on cell
membranes causing an irreversible permeabilization, which
leads to disruption of cellular homeostasis, activating apop-
totic pathways in tumor cells [43]. The main advantage of
IRE compared with other ablative techniques is the ability to
preserve the extracellular matrix, thus allowing ablation adja-
cent to critical structures as nerves, vessels and biliary ducts;
IRE is therefore the safest ablative approach for tumors
encasing major peripancreatic vessels [43,44].
A typical IRE procedure for a solid tumor, with a size of
approximately 3 cm in diameter, uses 90 pulses with an
ultra-short pulse length of 100 ls; for bigger lesions, more
application can be overlapped to reach the desired volume
with well-demarcated margins that are usually clearly identi-
fied by imaging. This relatively short ablation time for IRE
may correlate with reduced anesthesia time, reduced post-
ablation pain, decreased ablation-related complications,
decreased overall cost of ablation treatment.
Irreversible electroporation has been proposed for palli-
ation of unresectable tumors of the pancreas, as a bridge
therapy before surgery, and also as a technique for intrao-
perative ‘margin augmentation’, in order to reach R0 resec-
tion in technically unresectable pancreatic tumors [45]. Open,
laparoscopic and percutaneous approaches have been eval-
uated for IRE. In most cases, percutaneous IRE was per-
formed under CT guidance, with encouraging results in
terms of feasibility, safety and effectiveness [46,47].
Preliminary studies [48,49] reported successful percutaneous
US-guided IRE of pancreatic cancer, without significant pro-
cedure-related complications. Månsson et al. [50] reported a
median survival of 7 months after percutaneous US guided
IRE of pancreatic cancer; the median time from IRE was
6.1 months to local progression and 2.7 months to observa-
tion of metastases. With larger studies, data on safety and
overall survival after percutaneous US-guided IRE could be
obtained to confirm its long-term efficacy within a multidis-
ciplinary approach to unresectable pancreatic cancer.
Non-invasive non thermal techniques
High intensity focalized ultrasound
Ultrasound is a form of mechanical energy, represented by a
wave of compression and rarefaction alternating each other,
that propagates through a liquid or solid medium (e.g., tis-
sues) yielding energy during its path. The difference between
diagnostic US and HIFU is the amplitude and transmission of
ultrasound waves. In HIFU, the US transducer is spherically
curved, allowing ultrasound waves to be focused at the cen-
ter of curvature. This can result in amplification of the pres-
sure amplitude by a factor of 100 at the focus. The lesion
targeting and monitoring during HIFU treatment, could be
US-guided (USgHIFU) or MR-guided (MRgHIFU). The mechan-
ism of tissue damage with high-energy ultrasound is medi-
ated both by a thermal and a mechanical effect (Figure 1).
Thermal damage results from a temperature increase
between 55 C and 85 C 12 in the treated volume, which
causes cell coagulative necrosis. The mechanical effects
produced by HIFU are cavitation, microstreaming and radi-
ation force [51–54].
There are few preliminary studies reporting the results of
HIFU impact on pancreatic cancer patients survival rates
[55–58]. The median overall survival and median time to pro-
gression, range from 6 to 11 months and from 5 to
8.4 months, respectively [57,58]. One-year survival rates after
HIFU can reach 30.8–42% [59,60] and seems can prolong
patients survival (median survival of 13 months) [61].
Side effects reported after HIFU are mild to severe
abdominal pain (in 5.9% of cases), edema (4.1%) and skin
burns (1.7%) [60,62]. The most dangerous complication is
bowel perforation, that can occur when the intestinal loops
are near to the ultrasound beam path and the targeted area.
HIFU procedure, as a pain-relief technique, is completely
noninvasive, since there is no transcutaneous approach or
needle insertion, differently from other minimally invasive
interventional procedures.
HIFU has been shown to be effective in the treatment of
pancreatic cancer-related pain, with a range of 75–100% of
patients experiencing significant pain relief [54,55,60,63]. The
majority of treated patients refer an immediate and signifi-
cant antalgic effect that can last for months; the long-term
palliative effect is difficult to be evaluated since life expect-
ancy of patients with advanced stage disease is poor.
The main limitations of HIFU, are mainly related to the
imaging guidance: acoustic shadowing, reverberation, refrac-
tion and other acoustic artifacts are specific for the US imag-
ing. However, HIFU itself is affected by the same acoustic
artifacts, which may affect both the efficacy and the safety of
the treatment. In order to decrease acoustic shadowing arti-
facts, an adequate bowel preparation for reducing meteor-
ism, is usually required together with a specific slag-free diet.
By applying a slight to moderate pressure on the abdominal
surface, above the targeted area, bowel loops may also be
compressed or displaced, in order to achieve a better and
clearer acoustic window, for energy transmission to the tar-
get. Very high procedural costs and the treatment length are
the main weaknesses for the HIFU, along with the complexity
in safely tracking the pancreatic target due to the respiratory
artifacts, but technological research and development could
lead to cheaper and faster instruments.
Conclusions
Limited data are available on minimally invasive techniques
in pancreatic primary tumor ablation. The reported literature
highlights the necessity for larger studies analyzing not only
the single technique efficacy but also comparing the differ-
ent techniques available. None of the techniques reported
showed significant better results compared to the other ones
(Table 1). Current data suggest the application of minimally
invasive ablation techniques only in advanced pancreatic
tumor setting with palliative intent. The decision of which
ablating technique apply should be decided based on cen-
ter expertise.
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Figure 1. Case of a patient with symptomatic pancreatic adenocarcinoma treated with high intensity focused ultrasound. (a) Magnetic resonance Imaging demon-
strating pathologic pancreatic mass. (b) PET/CT scan demonstrating high FDG uptake of the pancreatic tumor. (c) Treatment with US-guided high-intensity focused
ultrasound. (d) PET/CT scan after treatment demonstrating lack of FDG uptake in the ablated area.
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